

Use this treatment card to write down the dates and times that you were administered Pluvicto® in case you need to provide this information during a hospital visit.

tor your treatment.

Please refer to the Patient Information Leaflet for the full guidance on preparing

- You are sexually active
- You have or have had any other type of cancer or treatment for cancer
  - You have or have had kidney problems

You have or have had tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty to stop bleeding, or frequent infections with signs such as fever, chills, sore throat or mouth or frequent infections with signs such as fever, chills, sore throat or mouth

- other ingredients of this medicine You have had low level of blood cell counts at a blood test
- If you are allergic to lutefium (1/1/Lu) vipivotide tetraxetan or any of the

Before you receive Pluvicto®, you should drink plenty of water in order to urinate as often as possible during the first hours after treatment. Tell your healthcare team if any of these apply to you:

Preparing for your appointment

## Your clinic information

# Your Pluvicto® ▼ (lutetium [¹¹¹Lu] vipivotide tetraxetan) treatment card

The information on this treatment card is intended for adult patients in the United Kingdom who have been prescribed Pluvicto\* for their PSMA-positive mCRPC, or for whom the prescribing decision has been made. This treatment card does not replace the Pluvicto\* Patient Information Leaflet that comes with your medication, or advice from your healthcare team. Always read the Pluvicto\* Patient Information Leaflet before starting your treatment and use Pluvicto\* exactly as your healthcare team has described.

#### Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse This includes any possible side effects not listed in the information leaflet that comes in the pack.

▼ The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please see www.mhra.gov.uk/yellowcard for instructions on how to report side effects.

mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen.

This material has been created and funded by Novartis Pharmaceuticals UK Limited.

UK | January 2025 | FA-11313166







#### After your appointment

After you have received Pluvicto<sup>®</sup>, keep drinking plenty of water so that you remain hydrated and urinate as often as possible. This will help to remove Pluvicto® from your body.

Pluvicto® is a radioactive treatment and a small amount of the Pluvicto® received may be transferred to others near you.

The doctor will inform you if you need to take any special precautions after receiving this medicine. This may include special precautions for you or your caregiver with regard to toilet use, showering, laundry, waste disposal, emergency medical assistance, unplanned hospitalisation or travelling.

Below you will find some examples of the precautions that need to be taken. Contact your doctor if you have any questions.

#### Possible side effects

If you experience any of the following serious side effects, tell your healthcare team right away:

- Tiredness, weakness, pale skin or shortness of breath
- Passing urine less often than usual or passing much . smaller amounts of urine than usual
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, sore throat or mouth ulcers

FINAL DOSE

Please note that the side effects listed above are not a full list of the known side effects. Please refer to the Pluvicto® Patient Information Leaflet for more information. Talk to your healthcare team about any side effects you experience during treatment with Pluvicto®. They may decide to temporarily delay your next dose, modify your dose, or completely stop your Pluvicto® treatment if you develop certain serious side effects.

### Precautions to reduce radiation exposure to others:

